Transgene is designing and developing next-generation immunotherapeutics against cancer
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our two therapeutic approaches
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
Discover invir.IO®
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene presented exciting preclinical data on TG6050, an intravenous Invir.IO® oncolytic virus
Transgene in a nutshell
ESMO 2022
Donwload Press release (PDF)
TG6002 en images
–> article Home actus
Press releases
- November 7, 2023 - Transgene reports business update and Q3 2023 financial position
- October 10, 2023 - Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- September 20, 2023 - Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
- September 14, 2023 - Transgene Announces Upcoming Investor Meetings
Last publications
- August 29, 2023 - Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
- May 26, 2023 - Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
- May 26, 2023 - Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
- April 16, 2023 - TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
- September 11, 2022 - Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- January 19, 2022 - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
- June 22, 2020 - Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
